11:18AM ET 12/10/2019 MT NewswiresFate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said Tuesday that its FT819 treatment exhibited enhanced tumor clearance compared...
3:51PM ET 12/09/2019 MT NewswiresFate Therapeutics' (FATE) shares were up nearly 45% in late-afternoon trading after the company said that new preclinical data for FT596, its multi-antigen...
12:02PM ET 12/09/2019 MT NewswiresFate Therapeutics (FATE) has an average rating among analysts of buy, with an average price target of $25. Price: 19.08, Change: +5.41, Percent Change:...
7:25AM ET 12/09/2019 MT NewswiresFate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $25. Price: 13.67, Change: +0.10, Percent Change: +0.74...